These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26318843)

  • 1. [Review of the current use of rituximab during 4 years in a French university hospital].
    Reynaud Q; Killian M; Robles A; Mounsef F; Camdessanché JP; Mariat C; Cathébras P
    Rev Med Interne; 2015 Dec; 36(12):800-12. PubMed ID: 26318843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
    Wongseelashote S; Tayal V; Bourke PF
    Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Rituximab in Connective Tissue Disease related Interstitial Lung Disease.
    Fitzgerald DB; Moloney F; Twomey M; O'Connell JO; Cronin O; Harty L; Harney S; Henry MT
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):215-21. PubMed ID: 26422566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with low-dose rituximab in off-label indications at two tertiary hospitals.
    Chay J; Donovan P; Cummins L; Kubler P; Pillans P
    Intern Med J; 2013 Aug; 43(8):871-82. PubMed ID: 23919335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.
    Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M
    Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
    Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
    Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of rituximab in autoimmune blistering diseases.
    Ahmed AR; Shetty S
    Am J Clin Dermatol; 2015 Jun; 16(3):167-77. PubMed ID: 25791770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
    Ebbo M; Grados A; Samson M; Groh M; Loundou A; Rigolet A; Terrier B; Guillaud C; Carra-Dallière C; Renou F; Pozdzik A; Labauge P; Palat S; Berthelot JM; Pennaforte JL; Wynckel A; Lebas C; Le Gouellec N; Quémeneur T; Dahan K; Carbonnel F; Leroux G; Perlat A; Mathian A; Cacoub P; Hachulla E; Costedoat-Chalumeau N; Harlé JR; Schleinitz N
    PLoS One; 2017; 12(9):e0183844. PubMed ID: 28915275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases].
    Catroux M; Lauda-Maillen M; Pathe M; De Boisgrollier de Ruolz AC; Cazenave-Roblot F; Roblot P; Souchaud-Debouverie O
    Rev Med Interne; 2017 Mar; 38(3):160-166. PubMed ID: 27836224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort.
    Lee WJ; Lee ST; Byun JI; Sunwoo JS; Kim TJ; Lim JA; Moon J; Lee HS; Shin YW; Lee KJ; Kim S; Jung KH; Jung KY; Chu K; Lee SK
    Neurology; 2016 May; 86(18):1683-91. PubMed ID: 27037228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.
    Quartuccio L; Zuliani F; Corazza L; Scaini P; Zani R; Lenzi M; Tavoni A; Sebastiani M; Baldovino S; Urraro T; Saccardo F; Sbreglia C; Mazzaro C; Pioltelli P; Fraticelli P; Filippini D; Gabrielli A; Perrella O; Scarpato S; Roccatello D; Zignego AL; Ferri C; Bombardieri S; Pietrogrande M; Monti G; Galli M; De Vita S
    J Autoimmun; 2015 Sep; 63():88-93. PubMed ID: 26255249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.